Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 8,398 Cr.
- Current Price ₹ 1,947
- High / Low ₹ 2,408 / 886
- Stock P/E 28.7
- Book Value ₹ 337
- Dividend Yield 0.26 %
- ROCE 17.5 %
- ROE 16.9 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.2%
Cons
- Promoter holding has decreased over last quarter: -2.64%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chlor Alkali / Soda Ash
Part of BSE Allcap BSE Commodities Nifty Microcap 250 Nifty Total Market BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,273 | |
245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,640 | |
Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 633 |
OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% |
2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 12 | |
Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 75 |
Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 127 |
Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 443 |
Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | |
67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 293 | |
EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 70.40 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 6% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 33% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 25% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 41% |
1 Year: | 112% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | 30% |
Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 42 |
Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,358 |
190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 904 | |
55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 676 | |
Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 2,979 |
364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 1,912 | |
CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 350 |
Investments | -0 | 29 | 71 | -0 | -0 | 0 | 0 | 21 | 21 | 21 |
106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 696 | |
Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 2,979 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
165 | 229 | 284 | 626 | 398 | |||||
-363 | -197 | -455 | -437 | -401 | |||||
69 | -32 | 195 | -200 | -8 | |||||
Net Cash Flow | -129 | 1 | 24 | -11 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 |
Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 |
Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 57 |
Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 67 |
Working Capital Days | 43 | 40 | 19 | -26 | -65 | -59 | 26 | 15 | 25 |
ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Nov - Intimation of One on One VC with NV Alpha Fund Management.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Nov - Participation in Anand Rathi Annual Flags Conference on Nov 18, 2024.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Nov - Epigral Limited (formerly known as Meghmani Finechem Limited) submits transcript of conference call held on 11th November, 2024 for Q2 FY25 results.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Nov - Audio recording of Q2 FY25 results conference call.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Epigral Limited to participate in Avendus Spark conference.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024Transcript PPT REC
-
Apr 2024TranscriptNotesPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Products:[1]
EPIGRAL is the fourth largest manufacturer of Chlor-Alkali and its Derivatives company in India. The company manufactures -
a. Chloralkalis: Caustic Soda Lye and Flakes, Liquid Chlorine, Hydrogen, Caustic Potash Lye and Flakes, etc.
b. Derivatives:The company has Chlor-Alkali Derivatives in the form of Chloromethanes and Hydrogen Peroxide